The combination therapy of major EGFR variant lung cancer treatments has yielded results at the annual conference of the European Society of Oncology (ESMO 2023). Combination therapy of Lexraza + Rybrevant has succeeded in improving major clinical evaluation indicators compared to Tagrisso monotherapy. Lexraza is a lung cancer treatment that targets the EGFR variant Exxon 19 and Exxon 21 L858R developed by Yuhan. We are confirming the possibility of a primary treatment for lung cancer in combination with Janssen's Exxon 20 target Rybrevant.

Tagrisso, in combination with platinum-based chemotherapy, has released clinical results in which encephalon has been effective in lung cancer patients. Tagrisso i